Targets › STK11
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.
Tumor suppressor serine/threonine-protein kinase that controls the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis and DNA damage response. Acts by phosphorylating the T-loop of AMPK family proteins, thus promoting their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4,…. (UniProt, Q15831)
Open in Phaseline: the race on STK11, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Jiatan Pharmatech | WX390 STK11 inhibitor | STK11 | Phase 2 | Gastric Type Adenocarcinoma (GAS) With STK11 Mutation; Solid Tumor | Dec 2026 |
Gastric Type Adenocarcinoma (GAS) With STK11 Mutation (1) Solid Tumor (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.